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Abstract 
Purpose: We propose a statistical multiscale mapping approach to identify microscopic and 
molecular heterogeneity across a tumor microenvironment using multiparametric MR (mp-MR).  
 
Methods: Twenty-nine patients underwent pre-surgical mp-MR followed by MR-guided 
stereotactic core biopsy. The locations of the biopsy cores were identified in the pre-surgical 
images using stereotactic bitmaps acquired during surgery. Feature matrices mapped the 
multiparametric voxel values in the vicinity of the biopsy cores to the pathologic outcome 
variables for each patient and logistic regression tested the individual and collective predictive 
power of the MR contrasts. A non-parametric weighted k-nearest neighbor classifier evaluated 
the feature matrices in a leave-one-out cross validation design across patients. Resulting class 
membership probabilities were converted to chi-square statistics to develop full-brain parametric 
maps, implementing Gaussian random field theory to estimate inter-voxel dependencies. 
Corrections for family-wise error rates were performed using Benjamini-Hochberg and random 
field theory, and the resulting accuracies were compared. 
 
Results: The combination of all five image contrasts correlated with outcome (P<10-4) for all four 
microscopic variables. The probabilistic mapping method using Benjamini-Hochberg generated 
statistically significant results (𝛼𝛼 ≤ .05) for three of the four dependent variables: 1) IDH1, 2) 
MGMT, and 3) microvascular proliferation, with an average classification accuracy of 0.984 ± 
0.02 and an average classification sensitivity of 1.567% ± 0.967. The images corrected by 
random field theory demonstrated improved classification accuracy (0.989 ± 0.008) and 
classification sensitivity (5.967% ± 2.857) compared with Benjamini-Hochberg. 
 
Conclusion: Microscopic and molecular tumor properties can be assessed with statistical 
confidence across the brain from minimally-invasive, mp-MR. 
 
Keywords: statistical multiscale mapping, multiparametric MRI, neuro-oncology, machine 
learning, random field theory 
 
Introduction 
Emerging targeted therapies interfere with specific molecules that promote tumor growth 
and infiltration based on patient-specific predictive cellular and molecular biomarkers [1]. 
However, heterogeneous genomic and phenotypic tumor microenvironments contribute to 
incomplete treatment by targeted therapy and promote tumor recurrence via a non-linear 
branched evolution of the cancer genome [2],[3]. Biopsy is currently the most effective method 
to assess patient-specific tumor biomarkers for targeted therapeutics, but clinical outcomes are 
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limited by tumor heterogeneity which cannot be assessed by invasive biopsy alone [1]. Medical 
imaging techniques that are minimally-invasive and assess cellular and molecular tissue 
characteristics across the entire tumor bed and tumor microenvironment (TME) hold the 
potential to significantly improve the characterization and treatment of aggressive brain tumors 
[5]-[7].  
Significant efforts are underway to develop tumor heterogeneity mapping techniques 
using minimally-invasive imaging including texture analysis [8]-[10]; proton [11],[12] and 
hyperpolarized 13C [13] spectroscopy; and most recently MR fingerprinting [14]. Generally these 
methods classify tumor properties at one of two levels: 1) volumetrically, by segmenting 
adjacent voxels together into classes, or 2) on a voxel-wise basis, treating each voxel 
independently. Volumetric segmentation techniques leverage spatial correlations in adjacent 
voxels that may be associated with tumor biology and/or the physical attributes of the 
acquisition process to improve SNR and classification accuracy. However, these improvements 
are balanced by a decrease in the theoretical spatial resolution of the parametric images, 
ultimately limiting the assessment of heterogeneity. Voxel-wise methods have a theoretical 
spatial resolution on the order of a single voxel, but suffer from significantly increased noise, 
which may be counteracted by the concomitant acquisition of multiple MR signatures. A recent 
voxel-wise algorithm demonstrated the ability to map tumor cellularity from three MR contrasts 
when biopsy findings were localized to the pre-surgical images [15]. Functional Diffusion Maps 
(fDMs) have also been estimated from ADC maps by identifying biopsy core locations on intra-
operative computed tomography and post-surgical high resolution 3D anatomical images [16]. 
Alternatively, MR Fingerprinting (MRF) is a promising voxel-wise approach that has been 
successfully used to parameterize important tumor tissue properties including T1, T2, and M0, 
as well as physical system properties including B0 and B1 [17]. There is some emerging 
evidence that MRF can be used to map functional tissue parameters including perfusion, 
oxygenation, and microvascular structure [18], but the extent to which the MRF technique can 
be applied to functional, cellular, and molecular imaging remains unknown. 
Here we propose to map cellular and molecular tumor properties throughout the TME in 
a voxel-wise manner by leveraging the growing dimensionality of clinical MR data. Our 
approach does not inherently rely on spatial correlation information or simulations of various 
tissue properties for classification. Instead, we hypothesize that the dimensionality of MR data 
alone provides a readily available vehicle to traverse tissue scale. We evaluate our hypothesis 
in three separate sub-steps: Sub-hypothesis 1) significant relationships (𝛼𝛼 ≤ 0.05) between 
macro- and micro-scale properties can be identified using elementary statistical testing when 
surgical pathology results are localized to the pre-surgical image space; Sub-hypothesis 2) 
non-parametric machine learning can classify microscopic properties from macroscopic images 
with high accuracy (≥ 95%) when traditional corrections for family-wise error rates are 
employed; and Sub-hypothesis 3) clinically-useful multiscale classification across the entire 
image space can be accomplished when the parametric images are treated as Gaussian 
random fields. 
Experimentally, we developed a data-driven model linking spatially registered core 
biopsy data to multiparametric MR. We used a diverse patient population consisting of more 
than 10 different disease classes, making the microscopic classifications more difficult but also 
more generalizable to a clinical population. We performed initial statistical evaluations on the 
model to determine the feasibility of predicting the biopsy findings from the MR values alone. 
We then evaluated the use of non-parametric machine learning to predict four clinically relevant 
properties: IDH1 mutation status, MGMT promoter methylation, cellular necrosis, and 
microvascular proliferation. Class membership probabilities output from the machine learning 
model were converted to chi-square statistical estimates using probabilistic distributions of the 
dependent variables identified a priori. The Benjamini-Hochberg algorithm controlled for family-
wise error rates (FWER), and the classification accuracy and sensitivity of the results were 
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optimized across a single classification tuning parameter. Finally, the machine learning model 
was extended to calculate chi-square (𝜒𝜒2) parametric maps across the entire brain of all 29 
patients. To improve statistical classification sensitivity in the image domain, we implemented 
Gaussian random field theory (RFT) to estimate the interdependence of voxels and then group 
statistical findings into thresholded clusters. We evaluated the images qualitatively by clinical 
experts and quantitatively by classification accuracy in the biopsy sample volume. 
Methods 
Study population and model development 
The Indiana University Institutional Review Board (IRB) approved this retrospective 
study without patient consent under the conditions that all patient data would be de-identified 
upon the completion of patient enrollment. De-identification consisted of removing all 18 HIPAA 
Privacy Rule identifiers from images, pathology reports, and clinical data. Accordingly, all dates 
were removed, but age and the difference in days between imaging and biopsy were retained 
for each patient. This study was not listed on ClinicalTrials.gov, and no part of the dataset 
presented here has been used or published on in the past. All source data used in this paper 
are openly shared with the 
radiology community for research 
replication and further analyses at 
http://www.iu.edu/~mipl. Inclusion 
criteria for this study required that 
the patients 1) had previously 
undergone targeted (stereotactic 
image-guided) core biopsy of the 
brain at our institution with at least 
three orthogonal plane images 
saved showing the location of the 
core; 2) had completed an MR 
scan a maximum of 60 days prior 
to biopsy that included at least T1 
weighting (T1w), T1 weighting post 
gadolinium injection (T1w-post), T2 
weighting (T2w), T2 weighting with 
fluid attenuated inversion recovery 
(T2-FLAIR), and diffusion 
weighted imaging (DWI). We 
specifically did not limit the study 
to a single tumor type (e.g. glioma) 
to ensure that the non-parametric 
model could be tested in a 
clinically-relevant population. 
Approximately 100 patients were 
screened, and 29 met the criteria 
for enrollment (N=29). The 
characteristics of the enrolled 
population are shown in Table I. 
All pathology reads and diagnoses 
were performed by two 
experienced neuropathologists, 
each with more than 10 years’ 
Table I. Subject population characteristics 
Parameter Value 
N 29 
Sex  
F 13/29 (45%) 
M 16/29 (55%) 
Age (y)  
Mean ± standard deviation 56.4 ± 19.3 
Range 23-89 
Pathology-based diagnosis 29 
Glioma 16 
WHO Grade IV 7 
WHO Grade III 2 
WHO Grade II 3 
WHO Grade I 4 
Metastatic carcinoma 4 
Breast 2 
Lung 1 
Melanoma 1 
Diffuse large B-cell lymphoma 2 
Schwannoma 1 
Reactive changes 2 
Abscess 1 
Germinoma 1 
Demyelination 1 
Normal 1 
Time between biopsy and imaging 
(days) 
 
Mean ± standard deviation 9.7 ± 9.1 
Range 0-37 
Biopsy samples  
Mean number of samples taken per 
patient ± standard deviation 
3.24 ± 1.8 
Mean sample volume (mm3) 4119.5 
 
*Note – Unless otherwise noted data are specified as number 
of patients. 
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experience practicing in an academic medical center. 
The five MR sequences were the only independent variables used in this analysis – for 
an overview of the acquisition parameters please see Supporting Information – Supplemental 
Table I. Approximately 90% of the acquisitions were performed at 1.5T (26 of 29), and 
approximately 70% of the anatomical sequences used 3D readout (101 of 145). All DWI 
acquisitions used two b-values (0,1000 s/mm2) and 3 orthogonal directions. For post-
processing, all images were initially registered to the T1w-post frame-of-reference for each patient. 
T1w was registered using a 12 degree-of-freedom (DOF) transform and minimization of a 
correlation ratio objective function [19]. T2w, T2-FLAIR, and DWI (B0-only) were registered using 
a 12 DOF transform and minimization of a mutual information objective function [20]. Apparent 
diffusion coefficient (ADC) maps were then registered to the individual T1w-post reference frame 
by applying the affine transformation matrix estimated for the DWI B0 images. We normalized 
voxels of each contrast to the mean value of uninvolved white matter determined by a spherical 
region-of-interest on the T1w-post. The 3-dimensional centroid of the biopsy core was identified on 
the T1w-post for each patient by visually comparing the three-plane neuronavigation plans (Figure 
1) to the pre-intervention MR images. We used the size of the biopsy core as reported in the 
pathology report to define a sphere centered at the location of the biopsy needle tip from which 
the image contrasts were extracted. This method ensured the feature matrix and subsequent 
machine learning model included only those voxels representative of biopsied tissues.  
We extracted the four dependent categorical variables from clinical pathology reports for 
each patient, classifying voxels as IDH1 mutation status positive (IDH1MS+) if the corresponding 
specimen contained any IDH1-R132H-positive cells based on immunohistochemistry, and 
voxels as MGMT promoter methylation status positive (MGMTPMS+) if present based on a 
methylation-specific PCR-based assay. When applicable, a clinical pathologist evaluated 
several representative microscopic sections for the presence of cellular necrosis (CNEC+) 
and/or microvascular proliferation (MVP+).  Because this study was not limited to primary brain 
tumors, the pathologist used their discretion to determine which tests should be applied on an 
individual patient basis, as a standard of care. Importantly, if the physician determined a 
variable need not be measured for a given patient, we classified it as negative for the analysis. 
 A biostatistician and co-author on this paper (S.C.) guided, oversaw, and reviewed the 
statistical analyses; an overview is given in Figure 2. 
Sub-hypothesis 1: Elementary statistical evaluations 
First, we calculated the normalized contrast values for the independent variables across 
the entire biopsy sphere for each patient, and combined them into a single feature vector 
mapping the five independent variables to the four outcome variables for each voxel. This 
resulted in a feature matrix of size 147,031 rows x 9 (binary) columns. A binary logistic 
regression was performed for each dependant variable by fitting a maximum-likelihood logit 
model. The regressions were sample weighted by the inverse of the probability of inclusion due 
to the sampling design to account for class imbalances [21]. The results characterized the 
 
Figure 1. Example neuronavigation targeting images for Subject 2. 
Subject 2 – Diffuse astrocytoma (WHO II)
35 mm3 core
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overall (combined) predictive power of the five image contrasts for each microscopic variable 
using the Wald 𝜒𝜒2 test and McFadden’s pseudo R2 [22].  
Sub-hypothesis 2: Multiscale classification without spatial information 
Next, we developed individual training feature matrices (𝐹𝐹𝐹𝐹𝑖𝑖,𝑡𝑡𝑡𝑡𝑡𝑡𝑖𝑖𝑡𝑡) and testing feature 
matrices (𝐹𝐹𝐹𝐹𝑖𝑖,𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡) for each patient, 𝑖𝑖. The 𝐹𝐹𝐹𝐹𝑖𝑖,𝑡𝑡𝑡𝑡𝑡𝑡𝑖𝑖𝑡𝑡 and 𝐹𝐹𝐹𝐹𝑖𝑖,𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 matrices included the following 
data: each of the 5 normalized MR contrast values in columns 1-5; the subject number (𝑖𝑖) in 
column 6; and the binary class flag for IDH1MS+, MGMTPMS+, CNEC+, and MVP+ in columns 7-10, 
respectively. The rows of 𝐹𝐹𝐹𝐹𝑖𝑖,𝑡𝑡𝑡𝑡𝑡𝑡𝑖𝑖𝑡𝑡 corresponded to the biopsied voxels across all patients 
except patient 𝑖𝑖; the rows of 𝐹𝐹𝐹𝐹𝑖𝑖,𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 corresponded to the biopsied voxels for patient 𝑖𝑖. A set of 
116 machine learning experiments (29 patients x 4 dependent variables) were then carried out 
using a leave-one-out design to ensure that in no case could data from the same patient be 
used for both training and testing. 
The machine learning classifier was a non-parametric weighted k-nearest neighbor 
design (wKNN) [23] with class weights calculated by the inverse Euclidean distance. The only 
tuning parameter used for classification was the number of neighbors, 𝑘𝑘, included in the class 
calculations. The classifier output was a 2-element vector for each voxel representing the 
 
Figure 2. Flowchart of the processing and statistical analysis steps. Endpoints resulting in 
statistical conclusions are outlined in green. 
Intermediate 
result: weighted 
mean accuracy from 
feature matrix
Group confusion 
matrix
Population-
derived expected 
distributions (ED)
29 Individual patient 
confusion matrices
29 Individual patient 
probability vectors
29 corrected
individual patient 
confusion matrices
Machine learning (wKNN)
Leave-one-out design with each patient 
trained by the combined data of all other 
patients. Outputs probabilities and classes.
29 Individual patient 
testing vectors
29 Individual patient 
training vectors
• IDH1 mutant
• MGMT methylation
• Cellular necrosis
• Microvascular proliferation
Preliminary result:
Individual parameter 
estimates and group-level 
significance
n = 29
• 5 MR contrasts each (independent predictors)
• 4 categorical microscopic (dependent) variables w/ spatial localization
Sample-weighted logistic 
regression for each predictor
Final result:
weighted mean 
accuracy from 
images
29 corrected
individual patient 
confusion matrices
Statistical transforms
• Step 1: Estimate 𝜒𝜒2 for each voxel based 
on the group expected dist.
Step 2 – FWER 
correction (B/H)
Step 2 – FWER 
correction (RFT)
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probability of membership in each binary class, calculated as the normalized sum of the inverse 
Euclidean distance. We transformed the probability vectors across the biopsy volume for each 
patient to a chi-square test statistic (𝜒𝜒2) using Pearson’s method [24]. The statistic compared 
our predicted class probability for each voxel with the background probability calculated for the 
entire voxel population across all patients. The chi-square transform was chosen (i.e. instead of 
z or t distributions) because the background probabilities could be explicitly calculated from the 
data. A clinical implementation of this algorithm would similarly have access to background 
population probabilities assuming the availability of a robust training dataset. The 𝜒𝜒2 values 
were then thresholded to a given 𝛼𝛼-value using standard statistical transforms. For FWER 
correction, a 𝑝𝑝-value threshold was calculated for each patient using the Benjamini-Hochberg 
procedure [25] at an 𝛼𝛼 of 0.05. We calculated a confusion matrix for each patient by choosing 
the class of greatest probability for all voxels that passed the FWER correction. The final 
measure of classification accuracy, 𝐴𝐴𝐴𝐴𝐴𝐴(𝑘𝑘), was calculated as the mean accuracy across all 29 
confusion matrices, with optimization across the tuning parameter 𝑘𝑘. The final measure of 
classification sensitivity, 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆(𝑘𝑘), was calculated as the percent of voxels sampled by biopsy 
that met the 𝛼𝛼 threshold. 
Sub-hypothesis 3: Multiscale classification across the image space 
𝜒𝜒2 parametric maps of each microscopic variable were then calculated as before for 
every voxel and overlayed on the T1w-post images using the tuning parameter that yielded the 
greatest value of 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆(𝑘𝑘) at an 𝐴𝐴𝐴𝐴𝐴𝐴(𝑘𝑘) ≥ 0.95. Because the images resulted in several orders 
of magnitude more voxels to be classified than in any of the 𝐹𝐹𝐹𝐹𝑖𝑖,𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 vectors, we determined that 
a less conservative FWER correction approach was necessary. As the 𝜒𝜒2 maps were smooth 
statistical fields, we used a mature FWER correction technique widely used in functional MRI 
which first estimates the spatial correlation of the statistical image and then identifies clusters of 
voxels which result in the expected Euler characteristic (EC) for a smooth statistical map [26]-
[28]. We performed both the spatial correlation and EC optimizations using FSL [29] [30], 
resulting in 𝜒𝜒2 parametric images for each dependent variable that controlled FWER at the 5% 
level. 
 
Results 
Study population and model development 
The enrolled population had a median age of 59 years (max 89, min 23) and had 16 
males (55%). The mean difference in time between imaging and biopsy was 9.7 ± 9.1 days. The 
biopsy-confirmed diagnoses included: sixteen gliomas (seven Grade IV, two Grade III, three 
Grade II, and four Grade I), four metastatic carcinomas (two breast, one lung, and one 
melanoma), two diffuse large B-cell lymphoma, one schwannoma, two reactive changes, one 
abscess, one germinoma, one demyelination, and one normal. A detailed overview of the 
enrolled subject population and demographics is given in Table I. 
Sub-hypothesis 1: Elementary statistical evaluations 
The combination of all five image contrasts was found to be significantly correlated with 
outcome (P < 10-4) for all four microscopic variables (Table II). IDH1MS+ had the greatest 
Table II. Overall prediction results of the combined (5) image contrasts from binary 
logistic regression analyses. 
Outcome Observations Wald 𝝌𝝌𝟐𝟐 P > 𝝌𝝌𝟐𝟐 Pseudo R2 
IDH1MS+ 147,031 18,520.37 10-4 0.2637 
MGMTPMS+ 147,031 8437.73 10-4 0.2455 
CNEC+ 147,031 22,245.20 10-4 0.2180 
MVP+ 147,031 17,136.48 10-4 0.0661 
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likelihood with a pseudo R2 of 0.26, followed by MGMTPMS+ (0.25), CNEC+ (0.22), and MVP+ 
(0.07). For a complete breakdown of the prediction results by individual image contrast, please 
see Supporting Information – Supplemental Table II. 
Figure 3 shows the parameter estimates (regression coefficients), demonstrating that 
characteristic patterns of the logits across the five predictors exist for each microscopic variable, 
even when accounting for the robust standard errors. Of note, IDH1MS+ and MGMTPMS+ exhibited 
strong negative correlations with T1w, and MGMTPMS+ also displayed a large negative correlation 
with ADC. CNEC+ demonstrated a strong positive correlation with T1w, while IDH1MS+ has a 
strong positive relationship with T2-FLAIR.  These initial findings provided a statistical 
foundation upon which our hypothesis could then be tested using the previously described 
machine learning techniques. 
 
Sub-hypothesis 2: Multiscale classification without spatial information 
The results of the machine learning optimization procedure are shown in Figure 4. Accuracy 
and the number of statistically significant voxels are shown in black and blue, respectively. The 
plots demonstrate that the tuning parameter 𝑘𝑘 has a large effect on the number of voxels which 
pass the FWER correction, and thus, indirectly, the overall accuracy calculation. There was 
similar classification behavior between IDH1MS+ and MGMTPMS+, in which classification accuracy 
generally increased with 𝑘𝑘, and then plateaued as the number of significant voxels began to 
decrease. No voxels passed the FWER correction for cellular necrosis at any value of 𝑘𝑘 that 
was tested. The classification accuracy of MVP had an approximately linear relationship with 𝑘𝑘, 
while the number of voxels passing the FWER threshold had an approximately inverse linear 
dependence on 𝑘𝑘.  
From the optimization plots, we chose a tuning parameter that maximized the accuracy 
and the number of voxels that passed the significance threshold. In keeping with our 𝛼𝛼 threshold 
of 0.05, we limited the minimum acceptable classification accuracy to be 0.95; thus, the optimal 
tuning parameter, 𝑘𝑘𝑜𝑜𝑜𝑜𝑡𝑡, was that which maximized 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆(𝑘𝑘) in the condition that 𝐴𝐴𝐴𝐴𝐴𝐴(𝑘𝑘) ≥ 0.95. 
Table III shows the optimized tuning parameter and classification results for the four 
microscopic variables. The values of  𝑘𝑘𝑜𝑜𝑜𝑜𝑡𝑡 for each outcome are also shown as vertical green 
bars in Figure 4. 
 
Figure 3. Regression coefficients for each microscopic variable across the 5 image 
contrasts. Error bars represent robust standard errors. 
 
IDH1MS+
T1w
T2w
T2-FLAIR
ADC
T1w-post
MGMTPMS+
CNEC+ MVP+
Parameter estimate
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Of the 3 variables that had significant findings (IDH1, MGMT, MVP) the average 
classification accuracy was 0.984 ± 0.02 and the average classification sensitivity was 1.567% ± 
0.967. Optimal classification results for the molecular markers IDH1MS+ and MGMTPMS+ were 
similar, both yielding an 𝐴𝐴𝐴𝐴𝐴𝐴(𝑘𝑘) of 1.0 and a 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆(𝑘𝑘) slightly greater than 2%. The optimal 
𝐴𝐴𝐴𝐴𝐴𝐴(𝑘𝑘) of MVP+ was 0.951 with a 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆(𝑘𝑘) of 0.2%. These results confirmed our hypothesis 
that multiscale classification could be performed without spatial information. However, the low 
number of voxels passing the correction threshold supported further evaluation of a FWER-
correction technique that was more sensitive to classification. 
 
Sub-hypothesis 3: Multiscale classification across the image space 
 Example images corrected by RFT using 𝑘𝑘𝑜𝑜𝑜𝑜𝑡𝑡 for IDH1MS+, MGMTPMS+, and MVP+ are 
shown in Figure 5 for 3 exemplary patients. Images for 4 additional patients are given in 
Supplemental Materials – Supp. Figure I. In Figure 5, the biopsy site for each patient is 
indicated with a yellow crosshair on the zoomed-in 𝜒𝜒𝑅𝑅𝑅𝑅𝑅𝑅2  maps (2nd row), and the original 
uncorrected probability maps generated by the machine learning model are shown in row 3. 
 
Figure 4. Accuracy (black; left vertical axis) and number of significant voxels (blue; right vertical axis) vs. 
the wKNN tuning parameter 𝑘𝑘. The optimal tuning parameter value (𝑘𝑘𝑜𝑜𝑜𝑜𝑡𝑡) maximized the number of 
significant voxels when 𝛼𝛼 ≤ 0.05. 𝑘𝑘𝑜𝑜𝑜𝑜𝑡𝑡 is indicated by a vertical green line for each outcome variable. 
Predicting IDH1MS+ Predicting MGMTPMS+
Predicting CNEC+ Predicting MVP+
𝐴𝐴
𝐴𝐴
𝐴𝐴
𝑘𝑘
𝐴𝐴
𝐴𝐴
𝐴𝐴
𝑘𝑘
𝐴𝐴
𝐴𝐴
𝐴𝐴
𝑘𝑘
𝐴𝐴
𝐴𝐴
𝐴𝐴
𝑘𝑘
𝑘𝑘 𝑘𝑘
𝑘𝑘 𝑘𝑘
Voxels
Voxels
Voxels
Voxels
Significant voxels
Significant voxels
Significant voxels
Significant voxels
𝐴𝐴𝐴𝐴𝐴𝐴 𝑘𝑘
𝐴𝐴𝐴𝐴𝐴𝐴 𝑘𝑘
𝐴𝐴𝐴𝐴𝐴𝐴 𝑘𝑘 𝐴𝐴𝐴𝐴𝐴𝐴 𝑘𝑘
𝑘𝑘𝑜𝑜𝑜𝑜𝑡𝑡𝑘𝑘𝑜𝑜𝑜𝑜𝑡𝑡
𝑘𝑘𝑜𝑜𝑜𝑜𝑡𝑡
Table III. Optimized results from the leave-one-out machine learning classification using 
Benjamini-Hochberg correction without spatial correlation information. 
Microscopic variable kopt 𝑨𝑨𝑨𝑨𝑨𝑨(𝒌𝒌) # of significant 
voxels 
𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺(𝒌𝒌) 
(%) 
IDH1MS+ 800 1.0 4197 2.2 
MGMTPMS+ 700 1.0 4399 2.3 
CNEC+ N/A 0.0 0 0 
MVP+ 3000 .951 405 0.2 
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Qualitatively the images demonstrate smooth statistical fields that are well localized to the tumor 
bed and TME. The quantitative classification results based on the 𝜒𝜒𝑅𝑅𝑅𝑅𝑅𝑅2 -corrected images are 
shown in Table IV. RFT demonstrated improved average classification accuracy (0.989 ± 0.008) 
and sensitivity (5.967% ± 2.857) compared with Benjamini-Hochberg. Notably, 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆(𝑘𝑘) for 
MVP+ increased to 9.9% using RFT compared with 0.2% with Benjamini-Hochberg. 
 
Figure 6 shows an example GBM subject had significant results for all 3 outcome 
variables that nearly covered the entire TME (Subject 8). The 5 predictor contrasts are shown 
along the left side of the image zoomed-in on the tumor bed and TME. The colormaps are 
windowed from 0 to the maximum 𝜒𝜒𝑅𝑅𝑅𝑅𝑅𝑅2  statistic (right side colorbars). Potential significant 
findings for MVP+ outside the T2-FLAIR abnormality (3 red speckles frontal and medial to the 
tumor) may hold important information related to microscopic disease spread. 
 
Figure 5. Results of the statistical mapping procedure for 3 select patients, with the location 
of the biopsy marked with a yellow plus sign. In all cases the 𝜒𝜒2 image with random field 
theory correction dramatically reduces the number of false positive findings and 
demonstrates smooth noise properties across space. 
T1w-post with 
𝜒𝜒
𝑅𝑅𝑅𝑅𝑅𝑅
2 overlays 
IDH1MS+ (green) 
MGMTPMS+ (blue) 
MVP+ (red)
wKNN-p
𝜒𝜒
𝑅𝑅𝑅𝑅𝑅𝑅
2
Patient 1
DX/PATH: Glioblastoma
IDH1MS: negative
MGMTPMS: negative
MVP+: positive
IDH1MS+ MGMTPMS+ MVP+ IDH1MS+ MGMTPMS+ MVP+
Patient 16
DX/PATH: Glioblastoma
IDH1MS: negative
MGMTPMS: negative
MVP+: positive
IDH1MS+ MGMTPMS+ MVP+
26
0 0 0
47 8 28
0 0 0
36 9 41
0 0 0
5 6
Patient 4
DX/PATH: Menangioma
IDH1MS: negative
MGMTPMS: negative
MVP+: negative
Table IV. Optimized results from the leave-one-out machine learning classification using 
random field theory correction including spatial correlation information. 
Microscopic variable kopt 𝑨𝑨𝑨𝑨𝑨𝑨(𝒌𝒌) # of significant 
voxels 
𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺(𝒌𝒌) 
(%) 
IDH1MS+ 800 1.0 4732 3.2 
MGMTPMS+ 700 0.987 7096 4.8 
CNEC+ N/A 0.0 0 0 
MVP+ 3000 .982 14610 9.9 
 
10 
 
 
Discussion and Conclusions 
Cellular and molecular heterogeneity is a significant driver of brain tumor morbidity that 
cannot be assessed by biopsy alone. This paper demonstrated three different methods to 
predict microscopic cellular and molecular properties of brain tumors from macroscopic, 
minimally-invasive clinical images. Elementary statistical evaluations demonstrated that 
significant relationships between the macroscopic and microscopic variables of interest did 
exist. Machine learning combined with a conservative correction for family-wise error rates was 
able to predict cellular and molecular properties with high accuracy but limited classification 
sensitivity (0.2-2.3%) for three of the four outcome variables. When spatial correlations across 
voxels were taken into account using Gaussian random field theory, high accuracy was retained 
with a significant increase in classification sensitivity (3.2-9.9%). The images generated by 
random field theory demonstrated acceptable noise and spatial resolution properties for clinical 
interpretation. Taken together, our results show that in vivo microscopic and even genomic 
mapping of human brain tumors may be clinically possible in the near future. 
The near-term implication of our findings is that researchers and clinicians utilizing 
machine learning to predict tumor heterogeneity should consider dimensionality to be one 
potential vehicle by which in vivo imaging signatures may be used to traverse scale. The rapid 
expansion of anatomical and functional MR sequences and the growing availability of hybrid 
imaging systems only serve to enhance this opportunity. The long-term implications of our 
findings are that it may be possible to map cellular and molecular tumor properties across both 
space and time during treatment, allowing for highly personalized treatment strategies that are 
not currently possible. For example, MGMT promoter methylation status can vary across the 
tumor bed and microenvironment [31] making treatment planning challenging. Patients who are 
determined by surgical biopsy to have MGMTPMS+ are expected to demonstrate good response 
to standard of care treatment with concomitant and adjuvant radiation therapy and 
chemotherapy with temozolomide [32], although this is almost always followed by relapse and 
eventual death. A subset of these patients are expected to also have undiagnosed MGMTPMS- 
properties, and thus may benefit from experimental personalized therapies [33]. The ability to 
 
Figure 6. Extensive visualization of statistical confidence ROI’s mapping genomic and 
cellular heterogeneity in a GBM patient. 
T1w
T1w-post
T2w
T2-FLAIR
ADC
16
0 0 0
161 63
Green = IDH1MS+
Blue = MGMTPMS+
Red = MVP+
RFT parametric image ( 𝜒𝜒2 )
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map MGMT promotor methylation status with a minimally-invasive in vivo probe would allow for 
better treatment selection and drug combinations than is currently possible. 
This study provides initial evidence in support of our hypothesis; however, there are 
significant limitations on the generalizability of our findings due to our study design. First, the 
retrospective design used in this paper did not allow for standardization of the 
immunohistochemical and molecular tests used across patients. This drawback required our 
analysis to rely on the clinical expertise of the pathology physicians in determining which tests 
were required at the individual patient level. Furthermore more comprehensive genomic 
evaluations (i.e. genome-wide association) could have been conducted to identify other 
predictor-outcome relationships than the four we investigated. The MR sequence parameters 
used for the five predictor variables varied across patients and locations which may have 
diminished their individual and collective effect sizes. The number of MR sequences was limited 
to 5, although many other sequences could have been used including perfusion imaging, 
chemical exchange saturation transfer, and MR spectroscopy. Finally, although the diversity of 
our patient cohort was clinically relevant, it very likely weakened our control over the 
experimental variables and ultimately reduced our statistical effect sizes compared with a highly 
controlled study focused on a single tumor or tissue type. However, the ubiquitous drawback of 
highly-controlled, single-disease radiomics studies is a failure to generalize to a clinically-
relevant patient population [34],[35]. 
In summary, we have demonstrated statistical relationships between routine 
multiparametric imaging signatures and underlying cellular and molecular properties of brain 
tumors. We have applied advanced statistical methods to correct for the family-wise error rate 
problem associated with whole-brain statistical parametric mapping, and have shown that the 
results have strong agreement with surgical biopsy. These results imply that cellular and 
molecular mapping of tumor heterogeneity from minimally-invasive images may be possible in 
the near future. 
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Supplementary Materials 
 
 
Supplemental Table I. Mean ± standard deviation of sequence parameters across the 5 
image contrasts. Parameters that are not specified varied too dramatically across sequence 
implementation (i.e. 2D vs. 3D read-out) or were not applicable to the sequence. 
Parameter T1w T1w-post T2w T2-FLAIR DWI 
TR (ms) - - 3461 ±  955.3 
5800 ± 
1751.2 
10208 ± 
4632.9 
TE (ms) 4.8 ± 3.4 3.9 ± 2.5 151.9 ± 95.8 330.4 ± 97.8 88 ± 14.3 
TI (ms) - - - 1937 ± 294 - 
Flip angle (°) - - - - 99 ± 28.5 
Pixel size (mm) 0.8 ± 0.3 0.9 ± 0.2 0.7 ± 0.2 1.0 ± 0.1 1.3 ± 0.3 
Bandwidth 
(Hz/pixel) 
173.0 ± 
22.1 
1088.1 ± 
142.3 
360.7 ±  
252.5 
569.8 ±  
221.1 
1088.1 ± 
142.3 
 
Supplemental Table II. Individual predictor results from the binary logistic regression 
analyses. 
Outcome Predictor Coefficient Robust 
Std. Error 
Z P > |Z| 95% Conf. 
Interval 
IDH1MS+ T1wp 0.204 0.140 1.45 0.147 -0.072 0.479 
T1w -3.211 0.562 -5.71 10-4 -4.313 -2.110 
T2w 1.110 0.036 30.63 10-4 1.039 1.182 
FLAIR 3.673 0.182 20.16 10-4 3.316 4.030 
ADC -0.459 0.029 -15.89 10-4 -0.516 -0.402 
cons -11.176 0.487 -22.93 10-4 -12.131 -10.221 
MGMTPMS+ T1wp 2.751 0.132 20.87 10-4 2.493 3.009 
T1w -4.161 0.175 -23.77 10-4 -4.504 -3.818 
T2w 2.275 0.069 32.76 10-4 2.139 2.411 
FLAIR 0.473 0.195 2.42 0.016 0.090 0.856 
ADC -4.494 0.237 -18.94 10-4 -4.959 -4.029 
cons -7.075 0.270 -26.21 10-4 -7.604 -6.546 
CNEC+ T1wp -0.798 0.020 -39.91 10-4 -0.837 -0.759 
T1w 4.449 0.053 84.29 10-4 4.345 4.552 
T2w 0.305 0.018 17.3 10-4 0.270 0.339 
FLAIR -2.918 0.030 -98.86 10-4 -2.976 -2.860 
ADC -1.119 0.015 -77.11 10-4 -1.148 -1.091 
cons 1.936 0.053 36.68 10-4 1.832 2.039 
MVP+ T1wp 0.049 0.027 1.85 0.065 -0.003 0.102 
T1w 1.175 0.102 11.5 10-4 0.975 1.375 
T2w 0.348 0.024 14.57 10-4 0.301 0.395 
FLAIR 1.492 0.030 50.31 10-4 1.434 1.550 
ADC 0.062 0.052 1.19 0.234 -0.040 0.163 
cons -7.433 0.104 -71.8 10-4 -7.636 -7.230 
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Supplemental Figure I. Statistical parametric maps thresholded by RFT for four additional exemplary patients. 
